The role of ZFP467 in mediating the anti-adipogenic and pro-osteogenic effects of parathyroid hormone: an in-vitro study by Leon Calle, Isabella
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2020
The role of ZFP467 in mediating
the anti-adipogenic and
pro-osteogenic effects of



















THE ROLE OF ZFP467 IN MEDIATING THE ANTI-ADIPOGENIC AND  
 
PRO-OSTEOGENIC EFFECTS OF PARATHYROID HORMONE: 
 










ISABELLA LEON CALLE 
 








Submitted in partial fulfillment of the 
 
requirements for the degree of 
 













































© 2020 by 
 ISABELLA LEON CALLE 










First Reader   
 Mina Moussavi, Ph.D. 





Second Reader   
 Clifford Rosen, M.D. 
 Director of Clinical and Translation Research, Maine Medical Center 
 Research Institute 
 Professor, Tufts University School of Medicine 





Third Reader   
 Phuong Le, M.S. 





Thank you, Dr. Clifford Rosen, Phuong Le, Hanghang Liu, and other members of 
the Rosen Laboratory at MMCRI, for allowing me to be part of this research. Your 
patient instruction and scientific advice were invaluable.  
 
Thank you Dr. Gwynneth Offner and Dr. Mina Moussavi for mentoring and 
advising me through Boston University’s Master of Medical Sciences Program.  
 
Thank you to my family and friends for your endless encouragement and selfless 




THE ROLE OF ZFP467 IN MEDIATING THE ANTI-ADIPOGENIC AND 
PRO-OSTEOGENIC EFFECTS OF PARATHYROID HORMONE: 
AN IN VITRO STUDY 
ISABELLA LEON CALLE 
ABSTRACT 
Parathyroid hormone (PTH) analogs are the main anabolic pharmacological agent 
for osteoporosis. PTH is an endogenous hormone, of which amino acids 1-34 bind the 
parathyroid hormone receptor (PTH1r), a G-coupled protein receptor expressed in 
kidney, fat, and bone. PTH increases trabecular bone mass by promoting the 
differentiation of the mesenchymal stem cell (MSC) into the osteogenic lineage. The Zinc 
Finger Protein 467 (Zfp467) is a potential downstream target of PTH1r and an important 
mediator of the MSC into the adipogenic lineage. Taken together, we ask whether Zfp467 
knockout cells will show greater osteogenic potential and increased sensitivity to PTH 
treatment. We also seek to investigate a mechanistic signaling pathway of PTH1r 
involving Zfp467. 
Calvarial osteoblast (COB) and bone marrow stromal cells (BMSCs) from Zfp467 
wild type (WT) and knockout (KO) mice were osteogenically differentiated and treated 
with either continuous (48h) or intermittent (6h/42h) PTH for 7-14 days. At 7 and 14 
days, alkaline phosphatase (ALP) and von Kossa staining were conducted, respectively. 
At 7 days after differentiation, qPCR was used to analyze genes involved in osteogenesis, 
adipogenesis, WNT signaling, and mitochondrial respiration. ELISA was used to 
measure cAMP levels. Seahorse XF96 assays were used to measure oxygen consumption 
	
	 vi 
rates (OCRs) and extracellular acidification rates (ECARs). Western blot was used to 
measure PTH1r. Additionally, adipogenic differentiation and Oil Red O staining were 
performed on BMSCs. 
ALP and von Kossa results showed that Zfp467 KO cells exhibited increased 
osteogenesis and an increased response to PTH treatment (continuous and intermittent) as 
compared to WT controls. qPCR analysis of Alp, Rankl, and Sp7 further supported an 
increased osteogenic potential of the KO. Also, Oil Red O staining revealed suppressed 
adipogenesis in KO BMSCs and qPCR analysis showed suppressed Adiponectin and 
Ppary in KO COBs. Additionally, Pth1r and PTH1r expressions were significantly higher 
in KO and short PTH treatments (~10m) induced a remarkable reduction in Zfp467 of WT 
cells. Furthermore, the KO showed suppressed Pgc1a, similar OCR, and increased ECAR 
as compared to WT. The KO also exhibited higher cAMP levels and was more responsive 
to PTH-induced increases of cAMP at 10 minutes of PTH exposure. However, qPCR 
analysis of Lef1 and Sost showed no difference regarding the WNT pathway.  
Our data support an anti-osteogenic and pro-adipogenic role for Zfp467. The KO 
displays less adipogenesis, more osteogenesis, and is consistently more sensitive to the 
osteogenic effects of PTH. The upregulation of Pth1r and PTH1r in KO cells offers an 
explanation for this increased sensitivity. We propose a mechanism where the 
suppression of Zfp467 upregulates Pth1r and PTH1r activation suppresses Zfp467, 
resulting in a constitutively active positive feedback loop. Further still, the KO shows 
potentially suppressed mitochondrial biogenesis (through Pgc1a analysis), similar 
oxidative phosphorylation (through OCRs), increased glycolysis (through ECARs), and 
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increased PKA signaling (through cAMP assays), yet their exact connections to the 
PTH1r-Zfp467 signaling pathway have yet to be investigated.  
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1.1: Bone Physiology  
The skeletal system is a key aspect of the human body. Bones protect vital organs, 
provide a bodily-frame and locomotion, and help support weight-bearing loads. Bones 
are made out of hydroxyapatite crystals, collagen type I, lipids, non-collagenous proteins, 
and water (K. E. Barrett & Ganong, 2010; Bilezikian et al., 2019; Costanzo, 2010).  
There are two main forms of bone: (1) Cortical or compact bone, which accounts for 80% 
of our body’s skeleton, and (2) trabecular or cancellous bone accounts for the remaining 
20%. Cortical bone is a denser structure found on the outside of bone. Due to its low 
surface area to volume ratio, bone cells lie in deep regions called lacunae and receive 
nutrients through processes extending into haversian canals containing blood vessels. The 
canal, along with the encircling collagen layers, is called an osteon or a haversian system. 
Trabecular bone, a spongier structure, is made up of plates of bone called spicules. The 
higher surface-area to volume ratio allows bone cells to sit on top of trabecular bone and 
receive nutrients that diffuse through the bone’s extracellular fluid (K. E. Barrett & 
Ganong, 2010). In the most general terms, bone cells include osteoblasts, osteoclasts, and 





Figure 1: The Structure of Bone.  
(A) Vertical and horizontal sections of cortical and trabecular bone can be seen, as well 
as associated structures: canaliculi, lacunae, haversian canals, and osteons. (Image 
reprinted from Barrett & Ganong, 2010). (B) Compact/cortical and cancellous/trabecular 
bone locations can be identified (top right). Close up of trabecular bone cross-section 
shows positions of bone cells (bottom right) (Image reprinted from Tate, 2008). 
 
Bone formation, also known as osteogenesis, occurs in two main forms: 
Enchondral and intramembranous bone formation. Enchondral growth occurs during fetal 
and adolescent development in the appendicular and axial skeleton. During this process, 
changes in the extracellular matrix and cellular adhesion properties allow mesenchymal 
cells to condense and express chondro-osteogenic transcription factors, such as Sox9, 
runt-related gene 2 (Runx2), and interestingly vascular endothelial factor (K. E. Barrett & 
Ganong, 2010; Bilezikian et al., 2019). The pre-chondrocyte population of condensed 
mesenchymal cells differentiate into chondrocytes, forming a template for future 
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osteogenesis and allowing the extracellular matrix to become rich in proteoglycans and 
fribrillar collagen type II. During fetal developmental limb growth, the proliferation of 
cartilage occurs from the proximal to distal axis. The cartilage template also grows in 
both appositional (width) and interstitial (length) directions. The former uses 
perichondrium as the primary source of chondroblasts, while the latter allows cartilage to 
grow along the longitudinal axis adding length to the bone. Beginning in the center of the 
diaphysis, the chondrocytes then begin a process of differentiation involving chondrocyte 
flattening and rearrangement into stacks, expression of genes such as Indian hedgehog 
homolog (Ihh) and parathyroid hormone-like peptide receptor 1 (Pthr1), and lastly 
hypertrophy and swelling. Osteoclasts, recruited by chemo-attractants, break up the 
matrix and hypertrophic chondrocytes undergo apoptotic death or trans-differentiation 
into osteoblasts. Additional osteoblasts, macrophages, and monocytic osteoclast 
precursors enter the area of bone growth through proliferating blood vessels. The bone 
forming center of the diaphysis extends as the growth plates continue to proliferate 





Figure 2: Enchondral Bone Formation 
On left and right sides are long bones before and after epiphyseal plate closure, 
respectively. In the growing bone (left) the epiphyseal plate and growing diaphysis shaft 
can be seen. Once growth ceases (right) extended vascularization and ossification are 
visible. (Image reprinted from Barrett & Ganong, 2010).  
 
During intramembranous growth, the more rapid form of osteogenesis, cortical 
and trabecular bone are laid down without a cartilage scaffold. The clavicles, mandible, 
maxilla and certain flat bones of the skull all undergo intramembranous growth (K. E. 
Barrett & Ganong, 2010). This process begins in the embryonic skeleton when 
mesenchymal cells gather and differentiate into capillaries, osteogenic cells, and 
osteoblasts. Osteoblasts then secrete osteoid, a matrix that subsequently calcifies and 
traps osteoblasts. The trapped osteoblasts become osteocytes in deep lacunae regions. 
Trabecular bone forms from the osteoid secreted around the capillary, while the 
periosteum and cortical bone form from the osteoid secreted from osteoblasts on top of 
the trabecular bone. The trabecular bone then crowds surrounding blood vessels, and 
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nearby cells and vessels, which eventually form red bone marrow (Betts et al., 2017). 
 
Figure 3: Intramembranous Osteogenesis (IO) 
(A) The beginning of IO. Mesenchymal cells gathered and osteoblasts secrete osteoid. 
(B) Osteoblasts are trapped and become osteocytes. (C) Formation of trabecular bone and 
periosteum. (D) Formation of cortical/ compact bone and red marrow. (Image reprinted 
from Betts et al., 2017). 
 
Osteoblast cells are mainly responsible for bone formation through collagen 
matrix production. However, research has unvieled the multifaceted roles of osteoblasts, 
which include direct regulation of mineralization and osteoclastogenesis, secretion of 
paracrine and autocrine factors, and even alterations of hemotopoeisis. Osteoblasts 
differentiate from stromal mesenchymal stem cells (MSCs) found in bone marrow and 
pass through the following stages: osteo-chondro progenitor, mature osteoblast, late 
osteoblast, and either apoptosis, lining cell, or osteocyte (Bilezikian et al., 2019; Chen et 
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al., 2016). Specific transcription factors are expressed at each stage of osteoblast 
differentiation, such as but not limited to, Runx2 and Osterix during early osteoblast 
progenitor comittment and alkaline phosphatase during intermediate osteoblast 
differentiation. These factors are not only important markers to identify osteoblast 
differentiation, but they are also needed for full differentiation and function of osteoblasts 
and proper skeletal growth. Further transcription factors involved in osteoblastogenesis 
include CCAAT-enhancer-binding proteins b and d (C/ebpb and C/ebpd), activator 
protein 1 (Ap-1), and transcription factor 4 (Atf4). However, in the presence of other 
transcription factors, MSCs can differentiate into adipocytes, chondrocytes, or myocytes 
instead of osteoblasts (Bilezikian et al., 2019).  
More generally, MSC differentiation is driven by a variety of factors: chemical 
factors such as transcription factors or hormones; physical factors such as mechanical 
strain; and biological factors such as aging and metabolism. More specfically, the MSC 
has a fine balance between the adipogenic vs. osteogenic differentiation pathways (Chen 
et al., 2016). While the MSC can differentiate into many cell types, the marrow 
adipocytes that arise from MSCs and are thought to be more closely related to the 
osteoblast than other MSC differentiated cells (Bilezikian et al., 2019; Horowitz et al., 
2017; J. Wu et al., 2018). Important transcription factors associated with adipocyte 
differentiation include C/epbs and peroxisome proliferator-activated receptor-g (Ppargg) 
(Chen et al., 2016). Once differentiated, adipocytes can be visualized and quantified 
using several staining techniques, such as oil-red-O (ORO) staining. Osteoblasts, on the 
other hand, can be stained with alkaline phosphatase stain and their minerlizations can be 
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stained through von Kossa and alizarin red stains.  
Osteoclasts, another important type of bone cell, are responsible for bone 
resorption. Derived from hematopoeitic stem cells differentiated into monocytes, 
osteoclasts require the presence of other cell types for differentiation. Specifically, the 
receptor activator for nuclear factor kappa beta ligand (RANKL) on an osteoblast, among 
other cells, can come into contact with RANK (the RANKL receptor) on a monocyte or 
pre-osteoclast. When this contact occurs, the monocyte or pre-osteoclast then 
differentiates into an mature multinucleated osteoclast (Figure 4). Mature osteoclasts use 
proton pumps to acidify the surrounding bone to a pH of 4, which dissolves 
hydroxyappetite. A shallow depression is formed as the collagen matrix is broken down 
(Figure 5). The broken down products, such as calcium, are transcytosed across the 
osteoclast and deposited into the interstitial fluid, increasing serum calcium levels. While 
the RANK-RANKL process (Figure 4) explains regulation between osteoclasts and 
osteoblasts at the cellular level, broader regulation is under paracrine control. The two 
main paracrine factors are the parathyroid hormone (PTH) and estrogen. The former 
accelerates bone resorption and the latter decelerates bone resorption (K. E. Barrett & 




Figure 4: Osteoclast Maturation 
RANKL on osteoblasts interacts with RANK on osteoclast precursor and forms a mature 
osteoclast that undergoes bone resportion. PTH and vitamin D (1,25(OH)2D3) both 
stimulate the expression of RANKL, while OPG can block RANKL by acting as a decoy 
receptor. PTH and vitamin D will be further explained. (Image reprinted from Human 






Figure 5: Osteoclast Undergoing Bone Resorption 
Membrane extensions called integrins help the osteoclast attach to the bone. Acid is then 
secreted from the ruffled apical membrane, creating a shallow depression in bone and 
bone erosion. (Image reprinted from Barrett & Ganong, 2010). 
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In addition to osteogenesis, the skeletal system remains dynamic through bone 
remodeling, the persistent coupled activity of osteoclasts and osteoblasts. Bone 
remodeling continuous to occur throughout life. The bone turnover rate in infants is 
100% per year and in adults it is 18% per year. This means that infants completely 
recycle their skeleton each year and adults recycle their skeleton every 5 to 6 years. 
Bones may also change shape slightly during remodeling, known as modeling drift. Also, 
in trabecular bone remodeling takes place on the surface, while in cortical bone 
remodeling takes place deep within the bone. The stresses and strains imposed by gravity 
are part of the reason why bone remodeling occurs (K. E. Barrett & Ganong, 2010; 
Costanzo, 2010).  
1.2: Calcium Regulation and Parathyroid Hormone 
Calcium, the most predominant mineral in the human body, is mainly found in 
bone and serum and constitutes about 1.5% of body weight. The body cannot make 
calcium, but it must be acquired through the diet (Betts et al., 2017; Costanzo, 2010). 
About one-fifth of calcium found in bone is available for rapid exchange between bone 
and serum. This exchange is crucial in homeostasis because serum calcium levels are 
tightly maintained at about 10mg/dL (2.5mM). Deviation from ideal range can lead to 
cardiac and neuromuscular excitability problems and osteoporosis. Other hormones, such 
as PTH, calcitonin, and vitamin D, further help regulate calcium balance in the body 
(Costanzo, 2010).  
In this review, we will focus on the effects of PTH on osteogenesis, 
osteoblastogenesis, and adipogenesis. PTH is an 84 amino acid long peptide, of which 
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amino acids 1-34 are biologically active, meaning that PTH 1-34 analogs can also bind 
and activate the PTH receptor (Fan et al., 2017; Locklin et al., 2003a; Ozkurt et al., 
2004). Endogenously, chief cells of the parathyroid gland synthesize and secrete PTH. 
The calcium-sensing receptor (CaSR), a 7-transmembrane G-coupled protein receptor 
(GCPR) found on the surface of chief cells, binds calcium in the millimolar range. In low 
calcium conditions, less calcium is available to bind to the CaSR, leading to an 
accumulation of intracellular cyclin adenosine monophosphate (cAMP), activation of the 
PKA pathway, and ultimately PTH synthesis and secretion from the chief cell 
(Conigrave, 2016). This process of PTH synthesis and secretion is found on the top 
portion of Figure 6.  
After leaving the chief cell, PTH circulates in the blood stream and binds to the 
parathyroid hormone receptor. The main parathyroid hormone receptor (PTH1r) is 
expressed at high levels in the kidney and bone. In bone, PTH1r is found on the surface 
of osteoblasts and when activated it induces RANKL expression on osteoblasts, 
maturation of osteoclasts through the RANKL-RANK system (Figure 4), and resorption 
of bone (Figure 5). Bone resorption of calcium directly elevates plasma calcium levels, 
regaining homeostasis. To further increase blood calcium levels, PTH also promotes 
calcium reabsorption in the distal nephron and increases the body’s synthesis of active 
vitamin D (or 1,25(OH)2D3). In the intestines, vitamin D increases calcium absorption by 
increasing epithelium calcium channels and intracellular calcium binding proteins. When 
calcium homeostasis is regained, PTH secretion comes to a halt through a negative 
feedback loop: normal calcium levels allow more calcium to bind to the CaSR on the 
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chief cell, decreasing intracellular cAMP levels, stimulating the phospholipase C 
pathway, and decreasing PTH secretion (Betts et al., 2017; Conigrave, 2016; Costanzo, 
2010). 
While the CaSR pathway is described above, the exact downstream signaling 
pathway of PTH1r has yet to be elucidated. Like the CaSR, PTH1r is also a GCPR and its 
downstream targets are complex and varied, involving the AC/PKA/cAMP pathway and, 
at either higher levels of or different dosing regimens of PTH, the PLC/PKC signaling 
pathways (Bilezikian et al., 2019; Locklin et al., 2003a; Romero et al., 2010). Some 
researchers have found that PTH also uses the WNT signaling pathway, specifically by 
interacting with disheveled or low-density-lipoprotein receptor (LRP)5/6 at the plasma 
membrane or by decreasing Sost expression in osteocytes (Bilezikian et al., 2019; 
Mansoori et al., 2017; Romero et al., 2010; Wein, 2018; R. Yang & Gerstenfeld, 1996). 
In-vitro experiments have shown that the effects of PTH are blocked by PKA inhibitors, 
but not by PKC inhibitors, indicating that the PTH signaling pathway may be PKA-
dependent yet PKC-independent (Li et al., 2007). Further still, PTH may be an even more 
complex molecule, requiring being broken down even further: Researchers using 
florescence resonance energy transfer to measure PKA, ELISA to measure cAMP 
accumulation, and smaller analogs of PTH, found that the PTH pathway may be PKA 
dependent for PTH1-28 and PKA independent for PTH29-34. The same researchers 
found that PTH had the potential to activate PKC via PLC-independent, but PKA 
dependent mechanisms (Tong et al., 2017).  
Due to the complexity of the pathway, more research is needed to fully 
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understand PTH’s exact mechanism. Although decades of more research are needed, this 
understanding could eventually lead to pharmacological interventions that enable patients 
to better respond to endogenous PTH or clinical PTH analogs.   
 
 
Figure 6: Parathyroid Hormone Signaling Pathway  
Top: Chief cell showing CaSR signaling pathway leading to PTH secretion. Bottom: 
PTH1r signaling pathway on either bone or kidney involving, but not limited to, PKA, 
PKC, and WNT. While the early signaling pathways of PTH are known, the extensive 
mechanisms on bone resportion and bone formation have yet to be fully elucidated 




Furthermore, while PTH is secreted endogenously by chief cells, PTH is also 
manufactured and used clinically. Instead of increasing bone resorption as occurs 
endogenously, PTH1-34 analogs such as teriparatide and others, have been shown to 
increase bone formation and bone mass. The difference between PTH’s anabolic vs. 
catabolic effect on bone is its form of administration. When PTH is administered 
intermittently, as in daily, monthly, or even biyearly injections, PTH has anabolic effects 
(Lau et al., 2012; Lou et al., 2018). Specially, an intermittent regimen has been associated 
with increased trabecular bone formation through upregulated osteoblast related gene 
expression, enhanced differentiation of pre-osteoblast cells, suppressed osteoblast 
apoptosis, and suppressed formation of sclerostin in osteocytes (Bilezikian et al., 2019; 
Calvi et al., 2001; Dobnig & Turner, 1995; Keller & Kneissel, 2005; Locklin et al., 
2003a; Manolagas, 2000; Ogita et al., 2008).  
Contrastingly, researchers found that when PTH is administered through a 
continuous regimen it has catabolic effects on bone. Examples of continuous treatment 
regimens include the body’s endogenous secretion of PTH or an in-vivo experimental 
model of surgically implanting mini-osmotic pumps in the subcutaneous tissue of mice. 
These pumps continually administer PTH1-34. After two weeks with these pumps, the 
mice showed delayed fracture healing as compared to mice receiving the intermittent 
regimen of daily injections (Crowell et al., 1984; Yukata et al., 2018). These 
experimental results were confirmed through radiographs, micro-computed topography 
analysis, quantitative histomorphometry, and gene analysis (Yukata et al., 2018). These 




While in-vitro models tend to show increased osteoblastogenesis and bone 
formation in intermittent treatment regimens, modeling the in-vivo effects of PTH 
analogs in-vitro has been challenging and not always consistent (Locklin et al., 2003a; 
Luttrell et al., 2018). Researchers have explored the biphasic effects of PTH in-vitro by 
keeping PTH in the media for full 48-hour cycle (continuous) or for only 6 hours of a 48-
hour cycle and then changing the media to fresh, PTH-free media (intermittent) (Locklin 
et al., 2003a; Ogita et al., 2008). While this treatment regimen lead to increased 
osteogenic staining and osteoblast-related gene expression in intermittently treated 
samples as compared to the continuously treated samples, other researchers have found 
no difference in osteogenic factors between intermittently vs. continuously treated 
samples (Luttrell et al., 2018). How PTH’s dosing regimen affects its downstream 
signaling pathway, leading to differential effects on bone formation, has yet to be fully 
explained and confirmed through consistent, repeatable experimentation.   
1.3: Zinc Finger Protein 467  
The Zinc Finger Protein 467 (Zfp467) is hypothesized to be a key downstream 
target of the PTH signaling pathway and its corresponding protein, ZFP467, an important 
mediator of the MSC’s differentiation into the adipogenic vs. osteogenic lineage. PTH’s 
stimulation of bone formation is attained through a quick and transitory induction of 
regulatory genes, among other methods. Through a genome wide approach involving 
cDNA microarray and quantitative real-time PCR on a stromal cell line, researchers 
Quach et al. found that Zfp467 (inhibition) was an immediate-early response gene to PTH 
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treatment. This finding implies that Zfp467 is a key regulatory factor in the PTH 
signaling pathway (Quach et al., 2011). 
Furthermore, Zfp467 was originally identified by researchers in search of a 
mRNA inducible by Oncostatin M, a member of the IL-6 family of cytokines. 
Subsequently, the ZFP467 protein was isolated from mouse hematogenic endothelial LO 
cells (Nakayama et al., 2002). Today, it is known that ZFP467 is a DNA binding protein 
that binds to GC rich regions of DNA and basal regulatory factors. ZFP467 is a 
transcription factor, belonging to the Krüppel-like family and containing 12 repeats of 
C2H2 motifs. Furthermore, ZFP467 is a ubiquitously expressed protein found to be 
implicated in cellular proliferation, differentiation, and development (Nakayama et al., 
2002; Quach et al., 2011; You et al., 2012, 2015). Our lab created Zfp467 knock-out mice 
for experimentation on its importance in the PTH signaling pathway, which will be 
further elaborated upon in this thesis. 
1.4: The Crux - Zinc Finger Protein 467 and Parathyroid Hormone Interaction 
Evidence showing that PTH administration can enhance the differentiation of pre-
osteoblast cells and reduce adipogenesis, supports PTH as an important mediator of the 
MSC into an osteogenic, as opposed to the adipogenic, lineage (Bilezikian et al., 2019; 
Mansoori et al., 2017; Quach et al., 2011; Romero et al., 2010; Wein, 2018; R. Yang & 
Gerstenfeld, 1996). Furthermore, mice that are haplo-insufficient for the parathyroid 
hormone related protein (PTHrP), a protein produced in healthy and carcinogenic tissues 
that also binds to and activates the PTH1r, show low bone volume, reduced 
osteoprogenitor recruitment, and increased marrow adiposity (Martin, 2005; Moseley et 
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al., 1995; Quach et al., 2011). This data supports that PTH drives MSC towards the 
osteogenic lineage as opposed to the adipogenic lineage.  
While PTH drives cells towards the osteogenic lineage, Zfp467 is hypothesized to 
drive cells towards the adipogenic lineage. Specifically, Quach et al. found that injecting 
retroviral ZFP467 in mice doubled their marrow adipocytes and that ZFP467 
transactivated the Ppargg response element, an essential transcriptional regulator of 
adipogenesis (Quach et al., 2011). This data supports ZFP467’s pro-adipogenic role 
through in-vivo and cellular experiments. 
Furthermore, researchers have noted inverse relationships on osteogenic vs. 
adipogenic factors after altering PTH vs. ZFP467 related experimental variables, 
respectively. Fan et al. noticed that deletion of PTH1r in early mesenchymal progenitors 
lead to increased Zfp467 expression in marrow adipocytes (Fan et al., 2017). Quach et al. 
noted that only 1 hour of PTH treatment decreased Zfp467 gene expression in calvarial 
osteoblasts (Quach et al., 2011). This evidence, along with the knowledge of PTH’s 
osteogenic and ZFP467’s adipogenic effects, bolster the inverse relation between ZFP467 
and PTH. Therefore, ZFP467 is a likely co-factor in transcriptional regulation of MSC 
cell fate towards the adipocytic, rather than osteogenic cell lineage. Despite the lack of 
published literature discussing the following question, we ask whether Zfp467 inhibition 
may enhance the response of osteogenic cells to PTH treatment, both in-vitro and in-vivo. 
1.5: Preliminary Data – In-Vivo, Untreated Experimentation 
Our laboratory developed Zfp467 global knock out mice to confirm the role of 
Zfp467 as a pro-adipogenic transcription factor and to determine whether Zfp467 knock 
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out (KO) mice would show enhanced osteogenesis in-vivo. Also, the following 
experimental methods were used to gather the preliminary data described in Section IV: 
dual-energy x-ray absorptiometry, micro-computed tomography, serum marker analysis, 
histomorphometry, staining and counting, RNA isolation and q-PCR. This preliminary 
data was contributed by Dr. Clifford J. Rosen and Phuong T. Le. 
The preliminary in-vivo data confirmed that Zfp467 KO mice showed enhanced 
osteogenic potential, and a decreased adipogenic potential, as compared to wild type 
littermate controls. When exposed to a high fat diet for 16 weeks before harvesting, our 
laboratory found that KO mice were protected from weight gain and marrow adiposity 
(although bone loss was similar to wild type littermate controls). Furthermore, the KO 
female mice had a significant increase in trabecular bone volume, a measure usually 
observed after PTH treatment although none was given. This supports enhanced 
osteogenic potential in the KO genotype. These mice also showed a reduction in 
peripheral fat and marrow adipose tissue, supporting decreased adipogenic potential. 
Furthermore, KO mice showed a significant reduction in major adipogenic differentiation 
factors (C/ebpa and, Pparg, Fabp4, leptin and adiponectin) and a significant 
upregulation in osteogenic genes (alkaline phosphatase, osterix/Sp7 and Pth1r), further 
supporting Zfp467’s pro-adipogenic and anti-osteogenic role. Most importantly, whole 
bone and marrow gene expression of the KO mice showed a 40% increase in Pth1r 
expression compared to that of littermate controls, which could enable them to better 
respond to PTH treatment (although not tested in preliminary data). Altogether, the 




Given the published literature findings, our preliminary data, and most 
importantly a significant upregulation in Pth1r gene expression in Zfp467 KO mice, our 
laboratory was led to ask whether: (1) Zfp467 KO cells would also display enhanced 
osteogenic characteristics in-vitro, and (2) Zfp467 KO mice and cells would show a 
greater response to PTH treatment as compared to WT controls due to their Pth1r 
upregulation both in-vitro and in-vivo. While our lab seeks answers for both in-vitro and 
in-vivo experimentation, this thesis will focus on in-vitro experimentation.  
1.6: Aims and Hypothesis 
This review will focus on in-vitro experimentation supporting a critical role for 
Zfp467 in mediating the anti-adipogenic and pro-osteogenic effects of PTH in the marrow 
niche. Using osteoblast precursor cells (mainly calvarial osteoblasts cells) from both 
Zfp467 KO and wild type (WT) mice and several outcome measures (staining, real-time 
polymerase chain reaction, western blot, ELISA, and cellular respiration measures), we 
seek two main aims:  
1. To determine whether osteoblast precursors from KO mice show greater 
differentiation in osteogenic media than WT controls;  
2. To determine whether osteoblast precursors from KO mice show a constitutive 
upregulation of Pth1r and PTH1r and an enhanced response to PTH treatment in-
vitro. 
Given published literature findings and our preliminary data, we hypothesize that 
KO mice and osteoblast precursor cells will have an enhanced response to PTH treatment 
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as compared to littermate controls. Our hypothesis consists of multiple parts:  
1. PTH treatment will promote greater osteoblast differentiation in osteoblast 
precursor cells in osteogenic media as compared to vehicle treated cells.  
While this finding is established in the literature, we seek to confirm it both 
qualitatively and quantitatively using several staining techniques and q-PCR analysis of 
adipogenic and osteogenic genes.  
2. Zfp467 KO osteoblast precursor cells will show greater osteoblast differentiation 
in osteogenic media as compared to WT controls. 
While parallel findings are established in our preliminary in-vivo data and a few 
published literature in-vitro studies, we seek to confirm it qualitatively and quantitatively 
using several staining techniques and q-PCR analysis of adipogenic and osteogenic 
genes. 
3. PTH treatment will decrease the expression of Zfp467 in osteoblast precursor cells 
as compared to vehicle treated cells.  
While this finding is reported in only one publication, to our knowledge, we seek 
to assess it quantitatively using q-PCR gene analysis and western blot. 
4. Zfp467 KO osteoblast precursor cells will show a constitutive upregulation of 
Pth1r. 
While Pth1r gene expression was upregulated by 40% in our preliminary data, we 
seek to confirm the upregulation of PTH1r protein expression through western blot. We 
will also continue to test Pth1r gene expression through q-PCR.   
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5. A positive feedback loop: Zfp467 KO osteoblast precursor cells will exhibit an 
enhanced response to PTH treatment as compared to WT controls.  
If 1-4 hold true, we hypothesize that Zfp467 KO cells will enhance the effect of 
PTH on bone-fat balance as compared to WT controls in a positive feedback loop model 
system (Figure 7). 
 
Figure 7: Hypothesis of ZFP467 and PTH1r interaction: A Positive Feed Back Loop 
Researchers hypothesize that Zfp467 lies downstream of PTH1r. With PTH present, 
ZFP467 formation is inhibited. Thus, the subsequent inhibition of Pth1r by ZFP467 is 
removed, and more PTH1r is formed and brought to the plasma membrane. With more 
PTH1r, cells will demonstrate an increased response to PTH. Global Zfp467 KO cells are 
hypothesized to function in a parallel manner: with a global deletion of Zfp467, the 
subsequent inhibition of to Pth1r will be minimized, leading to more PTH1r formation 
and an enhanced response to PTH treatment (Image contributed by Hanghang Liu). 
 
We hope our experimental findings further elucidate Zfp467’s critical role in 
mediating the anti-adipogenic and pro-osteogenic effects of PTH in the marrow niche. A 
clearer understanding of Zfp467’s role in PTH signaling could not only further scientific 
knowledge but aid in developing targeted clinical therapies within the PTH signaling 
pathway. Such pharmacological interventions could improve the quality of life for 
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millions of osteoporosis patients on PTH analogues, such as abaloparatide, denosumab, 
and teriparatide, world-wide.  
 
Figure 8: Current Understanding of the PTH Signaling Pathway 
The PTH signaling pathway includes, but is not limited to, PKA, PKC, and WNT 
signaling pathways. With the given experimental evidence, we hypothesize that Zfp467 is 
downstream of PTH1r, providing a positive-feedback loop for the receptor. While it is 
scope for this thesis, our lab aims to identify the transcription factor(s) directly 
communicating with Zfp467 and Pth1r, illustrated above as TFX and TFY, and their 






Using C57BJ/6N-ZFP467 tm1 (KOMP)V1cg sperms obtained from UC Davis 
KOMP Repository (Davis, CA), in-vitro fertilization was performed to a B6.Cg-
Edil3Tg(Sox2-cre)1Amc/J Sox2Cre female (Jackson Laboratory, Bar Harbor, ME) to 
obtain Zfp467 knockout (KO) and wildtype (WT) control mice. Mice were maintained in 
polycarbonate cages with sterilized paper bedding. Mice were kept under 14:10 hour 
light: dark cycles in the barrier, an AAALAC-accredited animal facility at Maine Medical 
Center Research Institute. The Institutional Animal Care and Use Committee (IACUC) of 
Maine Medical Center reviewed and approved all experiments. Furthermore, the NIH 
guidelines for the Care of Use of Laboratory Animals were followed. While the in-vivo 
experiments used only female mice, the in-vitro experiments used both male and female 
mice. The genotype of all samples was confirmed using PCR analysis. 
2.2 Calvarial Osteoblast Cell (COB) Isolation and Culture 
 COBs were isolated from 8-10 Zfp467 WT and KO male and female pups at 3-5 
days after birth, as described previously (Kawai et al., 2011; Rosen et al., 1997). 
Following four digestions using collagenase P (Sigma, St. Louis, MO) and trypsin (Life 
Technologies Corporation, NY, NY), cells were resuspended in complete Dulbecco’s 
Modified Eagle Media (complete DMEM)  [DMEM (Life Technologies, Waltham, MA) 
+ 10% fetal bovine serum (FBS) (VWR, Radnor, PA) + 1% penicillin/streptomycin (PS, 
Life Technologies, Waltham, MA) + 2.5% non-essential amino acids (NEAA, Life 
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Technologies, Waltham, MA)] and placed into a 100 x 20mm tissue culture treated petri 
dishes (VWR, Radnor, PA) for further expansion. After a second passage, cells were 
plated at a density of 7.5x104 cells/12-well plate or 1.5x105 cells/6-well plate in complete 
DMEM media.  
2.3 Bone Marrow Stromal Cell (BMSC) Isolation and Culture 
 BMSCs were isolated from tibiae and femurs of 6-week-old female Zfp467 WT 
and KO mice as described in the previously established protocols (Maridas et al., 2018). 
Briefly, tibiae and femurs from 4 mice per genotype were collected and their distal ends 
were cut before their bone marrow was spun by centrifuging at 13,000 rpm for 15 
seconds. Cells were resuspended in complete Minimum Essential Medium Eagle - alpha 
modification (complete aMEM) [aMEM (Life Technologies, Waltham, MA) + 10% fetal 
bovine serum (FBS) (VWR, Radnor, PA) + 1% penicillin/streptomycin (PS) (Life 
Technologies, Waltham, MA)] and plated in one T150 flask per genotype. Once cells 
were confluent, usually between 24 to 48 hours, they were lifted using 0.25% trypsin 
EDTA (Life Technologies, Waltham, MA). Cells were split and platted at equal density 
in three 100 x 20mm tissue culture treated petri dishes (Falcon, Durham, NC). Once cells 
reached confluency, between 1-3 days later, these cells were plated at a density of 
7.5x104 cells/12-well plate or 1.5x105 cells/6-well plate in complete aMEM media.  
2.4 Osteoblastogenesis 
The media of bone marrow stromal cells and calvarial osteoblasts was changed 
every other day until cells were about 85% confluent. Only then was osteoblastogenesis 
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initiated as described in the previously established protocol (Maridas et al., 2018). 
Osteoblast differentiation media consisted of complete aMEM media, 50 µg/mL ascorbic 
acid (Sigma-Aldrich, Milwaukee WI), and 8 mM b-glycerol phosphate (Sigma-Aldrich, 
St. Louis, MO). If PTH treatment was planned for the given cell sample, vehicle and PTH 
treatment were given within the osteoblast differentiation media. Cell media were 
changed every two days. 
2.5 Parathyroid Hormone Treatment of COBs and BMSCs 
 Parathyroid hormone 1-34 bovine (Bachem, King of Prussia, PA) was diluted to 
1mg/mL stock PTH using vehicle solution (4mM HCl + 0.1% BSA). Once COBs and 
BMSCs were plated at densities previously described and 80-85% confluent, 
osteoblastogenesis and PTH treatment were initiated. The differentiated samples were 
split into four groups: (1) cells (exposed to osteoblast differentiation media alone), (2) 
vehicle, (3) 50nM PTH and, (4) 100nM PTH treatment. The vehicle was diluted to 
100nM with osteoblast differentiation media. The 50nM and 100nM PTH were made by 
diluting 1 mg/mL stock PTH with osteoblast differentiation media.  
Cells were treated with PTH either continuously or intermittently. Continuous 
treatment consisted of changing media every 48 hours for each treatment group until the 
termination of the culture. Intermittent treatment also involved changing media every 48 
hours, but after the first 6 hours of the media cycle, all groups were washed with warm, 
fresh osteoblast differentiation media and replaced with fresh osteoblast differentiation 
media, only without any treatments. In other words, in the intermittent treatment regimen, 
all PTH treatment was washed away and switched to osteoblast differentiation media 
	
25 
after 6 hours of exposure for the remaining 42 hours of the media cycle. PTH treatment 
was conducted on five sets of calvarial osteoblasts for each experiment.  
2.6 Osteogenic Staining (Alkaline Phosphatase, Von Kossa, and Alizarin Red) 
Alkaline phosphatase (ALP) was used to assess osteoblast differentiation in 
calvarial osteoblasts and bone marrow stromal cells on day 7 of osteogenic 
differentiation. The following treatment groups were stained: Cells (exposed to 
osteogenic media-alone), vehicle, 50nM PTH, and 100nM PTH. Cells were treated either 
continuously (48h) or intermittently (6h/42h). On day 7 of differentiation, cells were 
fixed with 10% neutral buffered formalin (Sigma-Aldrich, St. Lois, MO). The ALP kit 
was obtained from Sigma-Aldrich (St. Louis, MO). ALP Staining was performed 
according to the previously established protocol (Maridas et al., 2018). 
Von Kossa (VK) and alizarin red stains were used to assess mineralization in 
calvarial osteoblast and BMSCs after 14 days of osteogenic differentiation. VK staining 
was also performed on some cultures at day 7, 16, and 18 of osteoblast differentiation. 
Cells had been exposed to osteogenic media-alone, vehicle, 50nM, or 100nM of PTH 
treatment in either a continuous (48h) or intermittent (6h/42h) manner. After fixation 
with 10% neutral buffered formalin (Sigma-Aldrich, St. Lois, MO), von Kossa staining 
was conducted using 5% silver nitrate and 5% sodium thiosulfate (both from Sigma-
Aldrich, St. Lois, MO) according to the previously established protocols (Maridas et al., 
2018). Alizarin red staining was conducting according to a previously established 
protocol (Serguienko et al., 2018). Briefly, 1% alizarin red solution diluted in water 
(Sigma-Aldrich; pH 4.2) was used to stain the cells for 30 minutes at room temperature 
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and unbound alizarin red dye was removed with water. 
2.7 Adipogenic Differentiation and Oil Red-O (ORO) Staining 
 Bone marrow stromal cells were differentiated into adipocytes according to the 
previously established protocol (Maridas et al., 2018). Once cells were about 85% 
confluent, adipogenic differentiation was initiated with the addition of adipogenic 
reagents 0.5mM 3-Isobytyl-1-methylxanthine (IBMX), 1µM Dexamethasone (both from 
Sigma-Aldrich, St. Louis, MO), 1µM Rosiglitazone (Cayman Chemical, Ann Arbor, MI), 
and 10µg/mL insulin (Sigma-Aldrich, St. Louis, MO) to the Base Media [DMEM High 
Glucose (Life Technologies, Waltham, MA), 10% fetal bovine serum (FBS) (VWR, 
Radnor, PA), 1% penicillin/streptomycin (PS) (Life Technologies, Waltham, MA)]. 
Depending on the given day of the adipocyte culture, the adipogenic reagents were added 
differently in the Base Media (see Maridas et al., 2018). During differentiation, cells were 
either exposed to adipogenic differentiation media alone or treated with vehicle, 50nM, or 
100nM of PTH in a continuous (48h) or intermittent (6h/42h) manner as described above. 
Seven days after the start of adipocyte differentiation, cells were fixed with 10% neutral 
buffered formalin (Sigma-Aldrich, St. Lois, MO) and were ready for ORO staining.  
To observe adipogenesis, ORO staining was performed according to the 
previously established protocol (Maridas et al., 2018). Briefly, cells were fixed and then 
washed with 60% isopropanol (Sigma, St. Louis, MO) before staining with ORO working 
solution (60% 3.5mg/mL ORO stock solution diluted in water; Sigma-Aldrich, St. Louis, 
MO) for 15 minutes. Then, cells were washed a couple of times with water before being 
viewed under the microscope. Pictures were taken under 5x to 20x magnification in order 
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to assess adipocytes.   
2.8 Microscope Images and Quantification 
 Following staining, cells were imaged at 5x magnification with at least three 
images per well (image fields: top, middle, bottom). Experiments requiring staining were 
repeated five times in triplicate wells during each experiment.  
To quantify ALP staining, 18 randomly selected ALP-stained images were chosen 
per treatment group and the number of ALP stained cells were counted per image. The 
average number of ALP stained cells per treatment group was calculated and compared to 
the control group (Vehicle). ALP quantification graphs show fold change on the y-axis 
and treatment group on the x-axis. The results were graphed and analyzed for statistical 
analysis using Prism Software (GraphPad Software version 8, Inc., La Jolla, CA) 
To quantify alizarin red staining, acetic acid (10%) was added to the Alizarin Red 
stained cells for 30 minutes. The cells were then scraped off the plate, transferred into 
tubes, vortexed, and heated at 85ºC for 10 mins. Following spinning and supernatant 
transfer, 10% ammonium hydroxide was added to the samples. Absorbance at 405 nm 
was measured spectrophotometrically using a plate reader (MRX Dynex Technologies, 
Chantilly, VA) and values were normalized to a calibration curve. 
To assess ORO adipocyte staining quantitatively, 500uL to 1mL isopropanol was 
added to each well of the stained adipocyte plate for 30 minutes to extract the dye. The 
extracted dye was removed via pipetting and the absorbance at 490 nm was measured 
spectrophotometrically using a plate reader (MRX Dynex Technologies, Chantilly, VA). 
Values were calculated and analyzed using Microsoft Excel (version 16.33) and Prism 
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Software (GraphPad Software version 8, Inc., La Jolla, CA) 
2.9 Real-Time Quantitative Polymerase Chain Reaction (q-PCR) 
 COB and BMSC baseline and osteoblast differentiated samples with and without 
PTH treatment in either a continuous (48h) or intermittent (6h/42h) were analyzed using 
q-PCR to assess expression levels of 16 genes plus 2 housekeeping genes (all listed in 
Appendix 1). The genes analyzed are grouped into five categories: (1) main genes of 
interest; (2) osteoblast related genes; (3) adipocyte related genes; (4) mechanism/pathway 
related genes; and (5) other genes. Beta-actin and Hypoxanthine-guanine phosphoribosyl 
transferase (Hrpt1) were used as housekeeping gene and run on each plate. The samples 
represent the following treatment groups: baseline (before osteoblast differentiation), 
cells (exposed to osteoblast differentiation media and no PTH treatment), vehicle, 50nM 
PTH, and 100nM PTH. The latter four treatment groups underwent osteoblast 
differentiation for 7 days. Experiments were repeated five times per genotype and 
treatment regimen.  
Total RNA for COBs and BMSCs was isolated using TRIzol (Molecular Research 
Center, Cincinnati, OH). cDNA was generated using the High Capacity cDNA Reverse 
Transcription kit (Life Technologies, Carlsbad, CA), according to the manufacturer’s 
instructions. Quantification of mRNA expression was done using an AzuraQuant™ 
Green Fast qPCR Mix LoRox (Azura Genomics, Raynham, MA) and an IQä5 multicolor 
Real-Time PCR detection system (Bio-Rad, Hercules, CA). b-actin and hypoxanthine-
guanine phosphoribosyl transferase (Hprt-1) were used as internal standard control genes 
and run with each plate. Primers were purchased from Primer Design (Eastleigh, United 
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Kingdom) and Integrated DNA Technologies (IDT, Coralville, IA). Primers from Primer 
Design were tested to be 95-100% efficient.  
2.10 Western Blot 
Protein extraction of cell cultures was done by scraping culture wells after adding 
protein lysis buffer composed of 0.5 M Tris –HCl  [12.1g Tris base (Sigma-Aldrich, St. 
Louis, MO), 60mL water, adjusted to 7.9 pH with 6N HCl (Life Technologies, Waltham, 
MA)], 25% glycerol (VWR, Radnor, PA) and 20% sodium dodecyl sulfate (Bio-Rad, 
Hercules, CA). Protein quantity was estimated using the Pierce® BCA Protein Assay Kit 
(Life Technologies, Waltham, MA), according to the manufacturer’s guidelines. Twenty 
micrograms of protein were placed in a Mini-Proteanâ TGXÔ Precast Gels (Bio-Rad, 
Hercules, CA) and then transferred onto a polyvinylidene fluoride membrane (Bio-Rad, 
Hercules, CA), according to the manufacturer’s guidelines. The membrane was incubated 
for 1 hour in blocking media consisting of 5% nonfat dry milk in tris-buffered 
saline/Tween 20 (1 M Tris-HCl, 5 M NaCl, 0.1% Tween 20). Then, the membrane was 
incubated at 4ºC overnight in primary antibody diluted in blocking media. The membrane 
was washed in tris-buffered saline/Tween 20 and incubated for 1 hour in secondary 
antibody diluted in blocking media. Each dilution was performed according to the 
manufacturer’s instructions. Horseradish peroxidase substrate (SuperSignal™ West Dura 
Extended Duration Substrate, Life Technologies, Waltham, MA) and ChemiDoc Imaging 
Systems (Bio-Rad, Hercules, CA) were used for chemiluminescence detection. PTH1r 
antibody was purchased from Sigma-Aldrich (St. Louis, MO); The primary and ZFP467 
antibodies were purchased from Invitrogen (Waltham, MA, USA). The secondary rabbit 
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IgG HRP linked whole antibody was purchased from Sigma-Aldrich (St. Louis, MO).  
2.11 cAMP Measurement Assay (ELISA) 
 The cAMP levels of undifferentiated and differentiated COBs were assessed using 
the Mouse/Rat cAMP Assay Parameter™ Kit (R&D Systems, Minneapolis, MN). 
Differentiated COBs were divided into the following treatment groups: cells (osteoblast-
differentiation media only), vehicle, 50nM PTH, and 100nM PTH.  Both undifferentiated 
and differentiated osteoblast cells, with the varying durations of PTH treatment (10m, 
30m, 60m, 24h, 48, 72h), were washed with phosphate buffered saline. Cell plates were 
immediately wrapped in parafilm and stored at -80ºC. 
One to two days after freezing, cell samples were prepared using 0.1 HCl/Cell 
Lysis Buffer (diluted 1:5) then neutralized with 1N NaOH at 1:10 total sample volume. 
Biotinylated primary antibody and samples were added to each well of the Streptavidin 
Coated Microplate and was incubated for 1 hour on a horizontal orbital microplate shaker 
at room temperature. Following a wash, Mouse/Rat cAMP conjugate was added to each 
well and incubated for 2 hours on a shaker at room temperature. Lastly, substrate solution 
was added and incubated, followed by a stop solution. Then absorbance at 490 nm was 
measured using a plate reader (MRX Dynex Technologies, Chantilly, VA). All listed 
reagents were included in the Mouse/Rat cAMP Assay Parameter™ Kit (R&D Systems, 
Minneapolis, MN), except HCl (Life Technologies, Waltham, MA) and NaOH (Life 
Technologies, Waltham, MA). Results were analyzed on Microsoft Excel (version 16.33) 
and Prism Software (GraphPad Software version 8, Inc., La Jolla, CA). cAMP ELISAs 
were repeated three times and samples were run in duplicate.   
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Both intra and inter-assay variation coefficients for this kit were calculated by 
testing three different samples of known concentrations in twenty separate assays and 
reported by manufacturers. The intra-assay coefficient of variation ranged from 1.7 to 
4.0%, with the mean being 2.5%. The inter-assay variation ranged from 6.4 to 7.8%, with 
the mean being 7.33%. The sensitivity of the assay was calculated from eighty assays. 
The minimum detectable dose (MDD) of cAMP ranged from 0.01 to 1.54 pmol/mL, with 
the mean being 0.79 pmol/mL.  
2.12 Cellular Respiration Measurements 
 Bone marrow stromal cells and calvarial osteoblasts were plated with 180µL of 
complete aMEM or complete DMEM media, respectively, at 1,500 cells/96-well 
Seahorse XF96 Cell Culture Microplate (Seahorse Biosciences, Billerica, MA) until the 
cells became confluent. Then either non-differentiation media (complete aMEM for 
BMSCs or complete DMEM media for COBs) or osteoblast differentiation media was 
given with PTH treatment (groups: cells, vehicle, 50nM and 100nM) for the following 
lengths of time: 30 min, 1h, 2h, 7 days-continuous, and 7days-intermittent. The oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) were assessed using 
the XF96 Extracellular Flux Analyzer (Seahorse Biosciences, Billerica, MA), as 
described in a previously publishes study (M. Wu et al., 2007).  
The Mito Stress test (Seahorse Bioscience, Billerica, MA) was also used to assess 
mitochondrial changes during osteoblast differentiation and PTH treatment, as described 
in a previously published study (Guntur et al., 2014). Several mitochondrial 
phosphorylation inhibitors were used during the test: oligomycin (2.52µM; an F0-F1 
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ATPase inhibitor), carbonylcyanide p-(triflueormethoxy) phenylhydrazone (FCCP, 12.65 
µM; an uncoupler), and Rotenone (12.67 µM; an inhibitor of uncoupled respiration). All 
inhibitors are from Seahorse Bioscience, Billerica, MA. By measuring changes in assay 
media pH, the Mito Stress test also yields ECARs. OCR was also assessed during the 
Mito Stress test as described in a previously published study (M. Wu et al., 2007). The 
substrate for all assays was XF DMEM media (pH 7.4; Seahorse Bioscience, Billerica, 
MA), XF 1.0M glucose, XF 100mM pyruvate, and 200mM glutamine solution (all of 
which are from Seahorse Bioscience, Billerica, MA). Upon completion, cells were 
viewed under the microscope to test viability and results were normalized by cell 
number/well via fluorescence detection with Hoechst (Life Technologies, Waltham, 
MA). OCR values are shown as picomoles/min/cell and ECAR values are shown as 
mpH/min/cell. All Seahorse experiments were repeated three times per genotype and 
treatment regimen with at least five different wells per treatment group.  
2.13 Statistical Analyses 
Unless it is otherwise specified, reported data are given as a mean ± standard 
deviation of the mean (SD). Statistical differences were measuring using Student’s t-test 
and one-way or two-way ANOVA, followed by Bonferroni’s multiple comparison post 
hoc test where appropriate. All statistics were performed with Prism (GraphPad Software 
version 8, Inc., La Jolla, CA) and Microsoft Excel (version 16.33). p-values of less than 







3.1a Alkaline Phosphatase 
The initial stages of osteoblast differentiation include the expression of alkaline 
phosphatase (ALP). We performed ALP staining on COBs and found two main results: 
(1) Zfp467 KO cells show increased osteoblastogenesis as compared to WT cells in non-
PTH treated trials and, (2) KO cells show an increased sensitivity to the osteogenic 
effects of PTH as compared to WT. Results are described both qualitatively and 
quantitatively.  
Enhanced osteoblastogenesis in untreated KO samples can be seen in Figure 9. 
Quantitative observations (Figure 9A) showed a 1.8-fold increase in ALP staining cells in 
the KO sample as compared to WT. Although these results were not significant, an 
upward trend is visible. Qualitative observations (Figure 9B, showing 2 experimental sets 
with triplicate wells and 5x magnification images) continue to show more staining in the 
KO genotype, as compared to the WT. Although observations are more prominent in the 
5x images, trends are also visible in the well images. Out of five experimental sets, three 
intermittent sets and four continuous sets showed increased ALP staining in the KO 




Figure 9: ALP stain of COBs following 7-day osteogenic differentiation and no PTH 
treatment. 
(A) Quantitative ALP measure of 18 randomly selected images per treatment group. 
Results were not significant yet represent an upward trend. (B) Qualitative well and 5x-
magnification images of experimental sets 1 and 2 shown. WT and KO genotypes are on 
the top and bottom rows, respectively. Media-changing regimens followed a continuous 
(48h) or intermittent (6h/42h) treatment schedule, as labeled. Each treatment was 
conducted in triplicate wells. Full five sets shown in Appendix 2. 
  
We also observed that an increase in PTH-dose led to an increase in ALP staining. 
This osteogenic effect of PTH was hypothesized, as it has been confirmed experimentally 
and clinically for decades. Figure 10 shows that an increase in PTH dose, regardless of 




Figure 10: ALP stain of COBs following 7-day osteogenic differentiation and PTH 
treatment. 
(A and B) Whole plate images of sets 1 and 2, with the WT and KO genotypes on the top 
and bottom rows, respectively. Plate columns represent cells (non-treated), vehicle, 50nM 
PTH, and 100nM PTH, as labeled. Each treatment was conducted in triplicate wells. Both 
continuous (48h) and intermittent (6h/42h) data shown. (C and D) Corresponding 
representative well and 5x magnification images of experimental sets 1 and 2. Full five 
sets shown in Appendix 2.  
 
More surprising were the nuanced differences observed between continuous and 
intermittent treatment regimens. Researchers hypothesized that intermittent treatment 
would lead to anabolic effects on bone, while continuous treatment would have a 
catabolic effect on bone seen through decreased ALP staining, as observed in previously 
published literature (Locklin et al., 2003b). However, both intermittent and continuous 
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treatment regimens showed an increase in ALP staining. Specifically, an intermittent 
regimen led to maximum staining at 100nM PTH, while a continuous regimen led to 
maximum staining by 50nM, with not much change or a slight decrease at 100nM. 
Observed trends were consistent in nearly all 5 sets (see Figure 10 and Appendix 2).  
Furthermore, with the KO genotype showing an enhanced potential for 
osteoblastogenesis, we questioned whether the KO cells would be more sensitive to the 
osteogenic effects of PTH. Trends of an increased response to PTH in the KO genotype 
were observed qualitatively and significant findings were measured quantitatively. 
Results showed a statistically significant difference between KO-Vehicle vs. KO-50nM 
and KO-Vehicle vs. KO 100nM in the continuous regimen (p<0.03 and p<0.02, 
respectively), and between KO-Vehicle vs. KO-100nM in the intermittent treatment 
regimen (p<0.05). There was no statistical significance between WT-Vehicle vs. WT-
50nM or WT-Vehicle vs. WT-100nM (Figure 11). This data shows that the KO genotype 
is more sensitive to the osteogenic effects of PTH, as compared to WT. 
 
 
Figure 11: ALP stain quantification of COBs following 7-day osteogenic 
differentiation and PTH treatment. 
ALP count of 18 randomly selected images per treatment group. Cells treated on a 
continuous (48h, A) or intermittent (6h/42h, B) regimen with vehicle, 50 nM, or 100 nM 
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PTH. (A) Statistically significant differences in KO-Vehicle vs. KO-50nM (p<0.03) and 
KO-Vehicle vs. KO-100nM (p<0.02) were observed. (B) A statistically significant 
difference in KO-Vehicle vs. KO-100nM (p<0.05) was observed. WT results were not 
statistically significant. Significance was analyzed using a one-way ANOVA on Prism 8. 
  
3.1b Von Kossa 
Von Kossa (VK) staining results were not ideal in that the COBs appeared to 
produce few mineralization even by day 18 of osteogenic differentiation and VK stain did 
not cover the entire well in a manner consistent with previously published literature 
(Alves de Oliveira et al., 2010). Regardless, VK staining continues to trend towards 
enhanced mineralization in the KO genotype (Figure 12). 
 
Figure 12: VK stain of COBs following 7 and 16-day osteogenic differentiation and 
continuous PTH treatment. 
12-well plate columns represent cells (untreated), vehicle, 50nM PTH, 100nM PTH 
treatment, as labeled. Each treatment was done under a continuous regimen (48h) and 
	
38 
conducted in triplicate wells. WT and KO genotypes on the top and bottom rows, 
respectively. Further mineralization data are confirmed through alizarin red staining 
(Figure 14).  
 
Further qualitative trends observed through VK staining of treated cells are as 
follows: (1) An increase in PTH treatment dose increased mineralization only slightly; (2) 
continuous treatment showed more mineralization than intermittent treatment. These 
trends are visible in Figure 13.   
 
Figure 13: VK stain of COBs following 7 and 16-day osteogenic differentiation and 
PTH treatment. 
(A) Non-PTH treated COBs after continuous (48h) and intermittent (6h/42h) media-
change regimens following 7 days of osteogenic differentiation. Increased 
mineralizations in KO observed. (B) Continuous (48h) treatment regimen of PTH treated 
cells following 7 and 16-days of osteogenic differentiation. Increased mineralizations in 





regimen of PTH treated cells following 7 and 16-days of osteogenic differentiation. No 
clear pattern of mineralizations between genotypes was observed. In (B) and (C), 
representative well image and 5x magnification images shown. Plate columns represent 
vehicle, 50nM, and 100nM PTH treatments, as labeled. Each treatment was conducted in 
triplicate wells.  
 
3.1c Alizarin Red Stain 
To obtain another measure of mineralization, alizarin red staining (ARS) was 
conducted on one set of COBs. ARS appeared to stain COBs better than VK stain in that 
it covered the entire well and showed clear trends between dosage and genotype. These 
trends paralleled the ALP data. First, the KO showed increased mineralization as 
compared to WT, in non-PTH treated sample (Figure 14, Cell group). Second, an increase 
in PTH dose resulted in an increase in mineralization for KO cells only, especially under 
5x magnification. This supports increased sensitivity to PTH in the KO genotype, as 
compared to WT. Lastly, the continuous treatment regimen seemed to increase 
mineralization more so than the intermittent treatment regimen. While only one trial of 
ARS staining has been conducted, it shows promising results of a qualitative 





Figure 14: Alizarin red stain of COBs following 14-day osteogenic differentiation 
and PTH treatment. 
Representative well and 5x magnification images shown. Plate columns represent cells 
(untreated), vehicle, 50nM, and 100nM PTH treatment groups. WT and KO are shown on 
the top and bottom rows, respectively. Alizarin red captured COB mineralizations better 




Some adipocytes were observed in COBs isolated from 5 to 7-day old pups after 
14 days of osteogenic differentiation. Because this was an unexpected finding and due to 
Zfp467’s pro-adipogenic role, ORO staining was performed to assess adipogenesis. We 
hypothesized that the KO samples would exhibit decreased adipogenesis (or increased 
lipolysis) as compared to WT. Qualitative and quantitative data showed that PTH 
treatment inhibited adipocyte formation in both WT and KO groups, however, the KO 
group showed fewer adipocytes and had a better response to PTH induced lipolysis in all 
treatment groups (Figure 15). The data supports a pro-adipogenic role for Zfp467. 
Quantitative data showed that untreated KO cells exhibit significantly less adipose than 
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untreated WT samples (p<0.008 and p<0.001, Figure 16 A and B). Furthermore, the KO 
cells exhibit an increased response to the anti-adipogenic effect of PTH. As compared to 
vehicle-treated samples, a significant reduction in adipogenesis was observed under both 
continuous and intermittent PTH treatments at 50nM and 100nM doses, while the WT 
only exhibited a significant reduction with 100nM intermittent PTH treatment (Figure 16 
C and D).  
 
Figure 15: ORO stain of COBs following 14-day osteogenic differentiation and PTH 
treatment. 
Well and 5x, 10x, and 20x magnification images of cell (non-treated), vehicle, 50nM, and 
100nM PTH, are shown in columns 1-4 respectively. Continuous (48h) and intermittent 
(6h/42h) treatment regimens are shown for both WT and KO. Each treatment was 




Figure 16: ORO stain absorbance measures of COBs following 14-day osteogenic 
differentiation and PTH treatment. 
(A and B) Untreated COBs undergoing a continuous (48h) or intermittent (6h/42h) media 
change regimen. (C and D) Vehicle, 50nM, and 100nM PTH treated COBs. All p values 
of treated cells were ≤ 0.0001. All statistical significances were measured using a one-
way ANOVA on Prism 8. Each treatment group was conducted in triplicate wells. Data 
contributed by Hanghang Liu. 
 
While only one trial of COBs was stained with ORO, the trends support a pro-
adipogenic role for Zfp467 in COBs. Furthermore, one set of bone marrow stromal cells 





3.1e Bone Marrow Stromal Cells (BMSCs) 
To confirm that the pro-adipogenic and anti-osteogenic effects of Zfp467 are 
generalizable across multiple cell-types, several sets of WT and KO BMSCs were 
differentiated and stained. 
BMSC I: ALP and VK Stains 
Both ALP and VK staining confirmed an anti-osteogenic role for Zfp467. 
Untreated BMSC were underwent osteogenic differentiation for 7 days for ALP staining 
and 14 days for VK staining. Although only qualitatively observed, the KO in all trials 
showed an increase in ALP and VK staining as compared to WT (Figure 17 and 18). 
Because visible nodules were present, VK staining of BMSC could be used to quantify 
mineralization nodules in future experiments. This data supports an anti-osteogenic role 
for Zfp467 in BMSCs. 
 
Figure 17: ALP stain of BMSC following 7-day osteogenic differentiation. 
Representative well-images of three sets of non-PTH treated BMSC shown. WT and KO 
genotype on the upper and lower rows, respectively. Experiments involved 6 wells per 




Figure 18: Von Kossa (VK) stain of BMSCs following 14-day osteogenic 
differentiation.  
Representative well-images of three sets of non-PTH treated BMSC shown. WT and KO 
genotype on the upper and lower rows, respectively. A starker contrast between 
genotypes observed in sets 2 and 3. Experiments involved 6 wells per genotype per set.  
 
 
BMSC II: ORO Stain after Adipocyte Differentiation 
One set of BMSC was exposed to adipocyte differentiation media and given 
continuous and intermittent PTH treatments. A quantitative absorbance measure was also 
conducted. Qualitative results showed that PTH reduced adipogenesis in a dose 
dependent manner for both genotypes (Figure 19). Quantitative results showed that while 
the untreated KO cells exhibited similar adipogenesis as untreated WT, the treated KO 
cells showed significantly reduced adipogenesis by 50nM of PTH treatment (p<0.007 
continuous; p<0.0001 intermittent). The WT cells did not show a significance result at 
50nM of treatment, supporting an enhanced sensitivity to treatment in the KO genotype. 
By 100nM of PTH treatment, both WT and KO cells showed significant reduction in 
adipogenesis (p<0.0001; Figure 20). Although these ORO results are not as pronounced 
as those found with COBs, they follow the same pattern and show that the KO genotype 
is more sensitive to, and enhances the effects of, lower doses of PTH treatment across 
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Figure 19: ORO stain of BMSCs following 14-day adipocyte differentiation and 
PTH treatment. 
Well and 5x, 10x, and 20x magnification images of cell (non-treated), vehicle, 50nM, and 
100nM PTH treated BMSCs, are shown in columns 1-4 respectively. Continuous (48h) 
and intermittent (6h/42h) treatment regimens shown for both WT (top) and KO (bottom). 





Figure 20: ORO stain absorbance measures of BMSC following 7-day adipocyte 
differentiation and PTH treatment. 
(A) Untreated BMSCs show no statistical significance using a one-way ANOVA. (B) 
Continuously (48h) and intermittently (6h/42h) treated BMSC show that the KO 
genotype has a significant reduction in adipose by 50nM of treatment (p<0.007 and 
p<0.0001). Both genotypes show a significant reduction in adipogenesis by 100nM of 
treatment (p<0.0001). Significance measured using a one-way ANOVA on Prism 8. 
 
3.2: Gene Analysis (qPCR)  
The following q-PCR results represent the average of five trials. Non-
differentiated cells are represented in the baseline group, while osteogenically 
differentiated cells are represented in the cells (non-PTH treated), vehicle, 50nM-PTH, 
and 100nM-PTH groups. No difference between continuous vs. intermittent treatment 
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regimens was identified unless otherwise noted.  
3.2a Main Genes 
Gene analysis of Zfp467 and Pth1r resulted in four main findings. First, Zfp467 
was successfully knocked out of the KO samples, confirming our breeding success and 
experimental design. Second, the expression of Zfp467 did not decrease with PTH 
treatment, as we had hypothesized would occur in a feedback loop between Zfp467 KO 
and Pth1r expression (Figure 7). Third, Pth1r expression was upregulated in the non-
differentiated KO samples (i.e. KO-baseline vs. WT-baseline). This supports the 
hypothesized pathway of ZFP467 inhibiting Pth1r expression, however, the same results 
were not observed in differentiated samples (Cells and Vehicle). Lastly, PTH treatment 





Figure 21: Zfp467 and Pth1r gene expression of non-differentiated and 7-day 
osteogenically differentiated COBs. 
The baseline group represents non-differentiated cells. The cells, vehicle, 50nM, and 
100nM groups represent 7-day osteogenically differentiated and treated cells. Treatment 
was given continuously (48h) or intermittently (6h/42h), shown on the top and bottom 
rows, respectively. The left and right columns represent Zfp467 and Pth1r gene 
expressions, respectively.  
 
3.2b Osteoblast Related Genes: 
Alkaline phosphatase (Alp), osterix (Sp7), and receptor activator of nuclear factor 
kappa-B ligand (Rankl) gene expressions were measured. In both (48h) and intermittently 
(6h/42h) treated samples, the KO cells show the highest expression of osteoblast related 
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genes. This supports that PTH promotes osteogenesis and that KO is more sensitive to 
PTH as compared to WT. Furthermore, Rankl was upregulated in undifferentiated KO 
cells (intermittent) but the results were inconsistent.  
 
Figure 22: Osteoblast-related gene expressions of non-differentiated and 7-day 
osteogenically differentiated COBs.  
The baseline group represents non-differentiated cells. The cells, vehicle, 50nM, and 
100nM groups represent 7-day osteogenically differentiated and treated cells. Treatment 
was given continuously (48h) or intermittently (6h/42h), shown on the top and bottom 
rows, respectively. The left, middle, and right columns show Alp, Sp7, and Rankl 
expressions, respectively.  
 
3.2c Adipocyte Related Genes: 
To analyze adipocyte related genes adiponectin, fatty acid-binding protein 4 
(Fabp4), and peroxisome proliferator activated receptor- γ (Pparγ) gene expressions 
were measured. Results showed lower adiponectin and Ppary gene-expression in KO 
samples, supporting a pro-adipogenic role for Zfp467. Unexpectedly, a higher expression 
of Fabp4 was noted in the KO samples. Furthermore, while PTH treatment was predicted 
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to downregulate adipocyte gene expression, PTH trended towards an upregulation of 
adiponectin, Fabp4, and Ppary. Taken together, KO showed a lower expression level of 
the adipocyte related genes. 
 
Figure 23: Adipocyte-related gene expressions of non-differentiated and 7-day 
osteogenically differentiated COBs. 
The baseline group represents non-differentiated cells. The cells, vehicle, 50nM, and 
100nM groups represent 7-day osteogenically differentiated and treated cells. Treatment 
was given continuously (48h) or intermittently (6h/42h), shown on the top and bottom 
rows, respectively. The left, middle, and right columns show Adiponectin, Fabp4, and 
Ppary gene expressions, respectively. Results were not as consistent as main or osteoblast 
related genes, but visible trends still observed.  
 
 
3.2d Mechanism/Pathway Related Genes: 
Lymphoid enhancer-binding factor 1 (Lef-1), peroxisome proliferator activated 




We hypothesized that Lef-1, whose protein is involved in the WNT pathway, 
would be upregulated in KO and PTH treated samples, due to PTH’s known signaling 
pathway involving WNT (Bilezikian et al., 2019; Kyoto Encyclopedia of Genes and 
Genomes, 2019). As predicted, PTH treatment increased Lef-1 expression in all 
genotypes, but most strongly in the KO genotype. This data further supports KO’s 
increased activation of the PTH signaling pathway, specifically involving WNT, as 
compared to WT samples. However, there appeared to be no main effect with genotype 
alone, apart from treatment: WT-Baseline vs. KO-Baseline and WT-Cells vs. KO-Cells 
show similar results.    
Secondly, researchers found that Pgc1α expression was higher in WT and 
increased with PTH treatment. Pcg1α is a downstream target of the AMP-activated 
protein kinase (AMPK) pathway, which is known to be involved in regulating growth and 
reprograming metabolism. PGC1 α’s specific role involves mitochondrial biogenesis, a 
process of increasing mitochondrial mass (Kyoto Encyclopedia of Genes and Genomes, 
2017; Mihaylova & Shaw, 2011). This supports that ZFP467 is involved in mitochondrial 
energy expenditure and biogenesis, a process linked with aerobic respiration, higher 
glucose uptake in cells, and, in humans, endurance training (Holloszy, 2011; Valero, 
2014).  
Lastly, Sost expression was upregulated in the KO samples, as observed by Quach 
et al. (2011). Our data also revealed an increase in Sost expression with PTH treatment. 
This trend was surprising because sclerostin, a protein encoded by Sost, acts as an 
antagonist to LRP5 and LRP6 and is an inhibitor of the WNT/β-catenin signaling 
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pathway (Bilezikian et al., 2019; van Bezooijen et al., 2004; J. Wu et al., 2017). PTH, 
which uses the WNT pathway, has been known to downregulate Sost expression 
(Bilezikian et al., 2019). Given these results, the KO-100nM showed the highest 
expression of Sost. The intermittent KO-baseline samples were also unexpectedly high. 




Figure 24: Signaling pathway-related gene expressions of non-differentiated and 7-
day osteogenically differentiated COBs. 
The baseline group represents non-differentiated cells. The cells, vehicle, 50nM, and 
100nM groups represent 7-day osteogenically differentiated and treated cells. Treatment 
was given continuously (48h) or intermittently (6h/42h), shown on the top and bottom 






3.2e Other Genes: 
Addition genes were tested, yet their results showed no clear trends between 
genotype and treatment group. These genes include collagen-1 (Col-1), Zfp423, Zfp521, 
and CCAAT/enhancer-binding protein alpha (C/ebp-a). Col-1, a marker of 
osteoblastogenesis and mineralization, was predicted to be highest in the PTH-treated KO 
cells. Results showed no clear trends between genotype or treatment groups. Zfp423 
showed higher expression in the WT group as predicted, however, unlike the other gene 
that were tested on three sets of COBs, this gene was only tested on one set. Zfp521, 
producing an anti-adipogenic protein, was predicted to have the highest expression in the 
KO treatment groups. However, this trend was only observed in the intermittently treated 
group. Lastly, C/ebpa, an adipose marker and whose protein aids in red blood cell 




Figure 25: Col-1, Zfp521, and Cepba gene expressions of non-differentiated and 7-
day osteogenically differentiated COBs. 
The baseline group represents non-differentiated cells. The vehicle, 50nM, and 100nM 
groups represent 7-day osteogenically differentiated and treated cells. Treatment was 
given continuously (48h) or intermittently (6h/42h), shown on the top and bottom rows, 
respectively. The left, middle, and right columns shows Col-1, Zfp521, and C/EBP-a 
expressions, respectively. Trends were not consistent between treatment group or 
genotype. 
 
3.3: cAMP Measurement Assay (ELISA) 
cAMP-ELISA experiments revealed that KO cells have a higher level of cAMP 
expression than WT and that PTH increased cAMP expression. First, the KO genotype 
appeared to display higher levels of cAMP than the WT in samples exposed to PTH for 
up to 10 minutes. Undifferentiated KO cells displayed 3-fold higher expression levels of 













































































































































































































































































































lasted through osteogenic differentiation and up to 10 minutes of PTH treatment. After 10 
minutes, a pronounced drop in cAMP levels was observed, followed by the WT 
expressing slightly higher levels of cAMP than the KO samples. Second, PTH treatment 
increased cAMP expression: PTH-treated samples consistently expressed higher levels of 
cAMP than vehicle-treated samples. Taken together, the KO cells exposed to PTH for 10 
minutes showed the highest increase in cAMP expression. Furthermore, 50nM of PTH 
appeared to increase cAMP levels more than 100nM in samples exposed to PTH for up to 
10 minutes, regardless of genotype.  
 
Figure 26: cAMP ELISA assay results of undifferentiated and 7-day osteogenically 
differentiated COBs. 
The baseline group represents non-differentiated cells. The vehicle, 50nM, and 100nM 
groups represent 7-day osteogenically differentiated and treated cells. PTH treatment was 
given for four durations: 10m, 30m, 60m, and long-term exposure (ranging from 24h to 
72h). Treatment was given continuously (48h) or intermittently (6h/42h) only for 48h 




3.4: Cellular Respiration Measurements (Seahorse XF96)   
Cellular respiration measurements of COBs following 1 hour of 100nM PTH 
exposure revealed that KO cells enhance PTH-induced increases in extracellular 
acidification rates (ECAR), as compared to WT cells. While the KO genotype showed 
only slightly lower oxygen consumption rates (OCR) as compared to WT (i.e. vehicles), 
PTH treatment suppressed OCR in both genotypes. Furthermore, while PTH is known to 
increase ECAR levels, PTH only appeared to increase ECAR in the KO genotype (Barrett 
et al., 1997). Treatment in the WT (i.e. WT-vehicle vs WT-PTH) did not trend towards a 
difference in ECARs (Figure 27). 
Additional cellular respiration measures were also taken. These include (1) OCR 
and ECAR for the non-differentiated and 7-day differentiated samples, and (2) OCR and 
ECAR for COBs exposed to 30m and 2h of PTH treatment. While the non-differentiated 
and 2h PTH treated samples showed similar trends as described above, the 7-day 
differentiated and 30m PTH treated samples displayed no clear trends. 
 
Figure 27: OCRs and ECARs of COBs following 1h of PTH exposure. 
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100nM PTH treatment was given to COBs in osteogenic media. OCR and ECAR 
measures are shown on the left and right, respectively. OCR parallels oxidative 
phosphorylation rates and ECAR to parallels glycolysis rates. Five wells per treatment 
group were analyzed and experiments repeated 3 times. Data contributed by Hanghang 
Liu. 
 
3.5: Western Blot Analysis of PTH1r   
To further support our hypothesis and confirm a PTH1r levels, western blot 
experiments was run on untreated WT and KO COB and BMSCs. After controlling for 
the brightness of the housekeeping gene band, the COB and BMSC KO samples both 
showed a significant 1.5-fold increase in PTH1r protein as compared to WT (Figure 28 A, 
B). This finding further supports the positive feedback loop hypothesis leading to a 
reduced inhibition on Pth1r in the KO samples and an upregulation of PTH1r on the 




Figure 28: Western blot analysis of PTH1r of non-differentiated COBs and BMSCs. 
Bands at 52 kDa represent PTH1r and bands at 37 kDa represent GAPDH (control 
housekeeping protein). COB (A) and BMSC (B) samples both show a significant 1.5-fold 
increase in PTH1r in the KO samples as compared to WT. Significance analyzed using a 
T-test on Prism 8. Band brightness was analyzed using ImageJ. Experiment was repeated 






4.1: Revisiting Experimental Results  
4.1a Osteogenic Staining (ALP, VK, ARS) 
In summary, we used three osteogenic stains to measure osteoblastogenesis and 
mineralization. Each staining method showed that (1) Untreated KO cells exhibited 
increased osteogenic potential, as compared to WT; (2) PTH treatment increased 
osteoblastogenesis and mineralization in both genotypes; (3) KO cells were more 
sensitive to the osteogenic effects of PTH, as compared to WT. These results were 
observed qualitatively and quantitatively. We conclude these trends to further confirm 
Zfp467’s anti-osteogenic character. 
4.1b Adipocytic Staining (ORO) 
Although it was surprising to observe adipocytes in COB cultures, this has been 
established in previously published literature (Withers et al., 2017; J. Yang et al., 2019). 
Both qualitative and quantitative staining of these adipocytes showed that KO exhibited a 
lower adipogenic potential, especially with PTH treatment. We conclude these trends to 
further confirm Zfp467’s pro-adipogenic role and enhanced sensitivity to PTH in the KO 
genotype.  
4.1c Additional Stains – BMSC 
The pro-osteogenic potential and increased sensitivity to PTH of the KO genotype 
was also seen in BMSCs. Although five sets of each stain were not measured (as in ALP 
and VK COBs), three sets untreated BMSCs showed that KO genotype had more 
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osteoblastogenesis and mineralization, as compared to WT (through ALP and VK 
staining). These trends were clearer and more pronounced than with the COBs, possibly 
due to the BMSC having more PTH1r than the COB. Yet, in our western blot data COBs 
and BMSC KO cells both showed a 1.5-fold increase in PTH1r as compared to WT; 
however, more qPCR and western blot data comparing gene and protein expression levels 
of Pth1r and PTH1r in BMSC and COBs are needed to confirm whether one cell types 
upregulates PTH1r more. Furthermore, the reduced adipocyte differentiation found in the 
ORO results of BMSCs paralleled those of COBs. Overall, the BMSC data supported a 
generalizable, pro-adipogenic and anti-osteogenic, role for Zfp467 across multiple cell 
types.   
4.1d Gene Analysis (qPCR) 
The Zfp467 and Pth1r data confirm portions of our hypothesized feedback 
signaling mechanism (Figure 7). As expected, we noted an increased expression of Pth1r 
in KO cells by 25-50% as compared to WT. This increase in receptor is likely driving an 
increased sensitivity to PTH in the KO cells observed in staining. However, with PTH 
treatment we did not observe a decrease in Zfp467 expression. While only the former, and 
not the latter data, supports a positive feedback loop between Zfp467 and PTH1r, we 
would like to investigate other cell types or lengths of PTH-exposure before making a 
conclusion about the signaling pathway.  
The osteoblast-related (i.e. Alp, Sp7, and Rankl) gene expression data consistently 
showed that the KO genotype expressed more osteogenic differentiation and is more 
sensitive to the pro-osteogenic effects of PTH treatment, as compared to WT. 
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Specifically, the KO-100nM ranged from 1.5 to 3-fold higher expression levels of 
osteoblast related genes than WT-100nM. This increased trend was observed in all 
samples except the undifferentiated group (baseline). This data parallels osteogenic 
staining results and supports an anti-osteogenic role for Zfp467 through gene expression 
analysis of COBs.  
The adipose-related (i.e. Adiponectin, Fabp4 and Pparg-y) gene expression data 
showed a suppressed adipose gene expression in all undifferentiated KO samples, 
supporting a pro-adipogenic role for Zfp467. In differentiated samples, the KO genotyped 
showed a suppressed gene expression for Adiponectin and Pparg-y, but not for the 
Fabp4-continuous treatment trial. Based on known catabolic effects of continuous PTH 
treatment and multipotent differentiation of MSCs, we had predicted a potential increase 
of adipogenesis with continuous PTH treatment. However, we did not expect an 
upregulation of Fabp4. Apart from this one outcome, all other adipose gene expressions 
match the phenotypic trends observed with ORO staining. We conclude this data to 
support a pro-adipogenic role for Zfp467.  
Furthermore, our data show that the balance of MSCs towards an adipocyte vs. 
osteoblast lineage is more complex than just a bidirectional road. While the 
undifferentiated KO cells displayed a lower expression of adipocyte-related genes, they 
did not display a higher expression of osteoblast-related genes, as compared to WT. 
While these cells had not undergone differentiation, neither had their WT counterparts. 
While Zfp467 may have been important in driving a cell towards an adipogenic lineage, 
one or many more other factors are essential in driving the MSC towards the osteogenic 
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lineage, illuminating the complexity of MSC differentiation even apart from treatment.  
The signaling pathway (i.e. Lef-1, Pgc1a, Sost, Lef-1) gene expression data 
showed differential results regarding the WNT pathway, yet the KO genotype continued 
to show increased sensitivity to PTH. While Sost, whose corresponding protein is an 
inhibitor of the WNT pathway, expression was upregulated with PTH, so was Lef-1, 
whose corresponding protein is an active participant in the WNT signaling pathway. This 
pattern was observed in both continuously and intermittently treated samples. The results 
of Lef-1 are weighed more heavily, due to the consistent literature about PTH using the 
WNT pathway. Regardless, the treated-KO samples seemed have the highest expression 
levels of Sost and Lef-1, showing increased sensitivity to PTH in the KO genotype.  
4.1e cAMP Assay (ELISA) 
Our cAMP-ELISA data further supports increased sensitivity to PTH in the KO 
genotype. An increased PTH dose led to increased cAMP expression, which is consistent 
with literature stating that PTH1r utilizes the PKA-cAMP pathway (Conigrave, 2016b). 
The KO samples exposed to 10mM of PTH were especially sensitive to PTH induced 
increases in cAMP levels. We interpret these findings as support for PTH’s use of the 
PKA signaling pathway in a dose-dependent manner and as support for enhanced 
sensitivity of the KO genotype to PTH. Furthermore, after 10 minutes we noted a 
significant drop in cAMP levels in both genotypes, but especially in the KO genotype. 
Another small drop in cAMP expression was noted after 1 hour of PTH exposure. It is 
possible that in these later time points the PKA pathway is saturated and that the cells are 
switching to another signaling pathway or that PKA activation is the first step in a longer 
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chain of activation steps. More investigation is needed to test which, if any other, 
pathways are activated during later time points. 
4.1f Cellular Metabolism (Seahorse) and Pgc1a Gene Expression (qPCR) 
The cellular respiration outcomes include oxygen consumption rates (OCR), 
extracellular acidification rates (ECAR, both using Seahorse XF96) and Pgc1a 
expression levels (using qPCR). It has been established that OCR measures oxidative 
phosphorylation and ECAR measures glycolysis by assaying lactate production (M. G. 
Barrett et al., 1997; Zhang et al., 2012). Through an only slightly suppressed OCR 
measure, the KO genotype may exhibit lower oxidative phosphorylation, but more trials 
are needed to confirm this finding. Through clear suppression of OCR in treated samples, 
PTH appeared to decrease oxidative phosphorylation in both genotypes. Because PTH is 
known to increase anaerobic glycolysis, and therefore likely decrease aerobic respiration, 
this observation was expected (M. G. Barrett et al., 1997). Furthermore, the KO 
genotype’s increased ECARs suggest a naturally increased glycolysis rate and a more 
sensitive response to PTH induced increases in glycolysis rate than WT (i.e. KO-PTH vs. 
WT-PTH). It is unexpected that PTH treatment did not increase glycolysis for the WT 
cells; in fact, WT-vehicle and WT-PTH samples showed very little difference in 
glycolysis rates, supporting increased sensitivity in the KO genotype alone. However, 
more ECAR trials are needed before confirming these conclusions. Using qPCR analysis, 
the KO genotype showed suppressed levels of Pgc1a, a gene involved in mitochondrial 
energy expenditure and biogenesis. Mitochondrial biogenesis is associated with aerobic 
respiration, higher glucose uptake in cells, and, in humans, endurance training (Holloszy, 
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2011; Valero, 2014). Taken together, these data support enhanced sensitivity to PTH-
induced anaerobic respiration for the KO genotype. 
4.1g Western Plot (PTH1r) 
In both COBs and BMSCs, we noted a 1.5-fold increase in PTH1r in the KO 
genotype, as compared to the WT. While this increase had been confirmed using qPCR 
gene expression, this data represents the first-time an upregulation of PTH1r protein in 
the KO genotype was measured in our lab. This finding further supports a feedback loop 
model between ZFP467 and PTH1r, leading to an upregulation of PTH1r, across multiple 
cell types (Figure 7).  
4.1h Continuous vs. Intermittent Treatment 
Modeling PTH treatment in-vitro has been debated in the research community for 
decades. We also found it difficult to model the anabolic vs. catabolic effects of 
intermittent vs. continuous PTH treatment that has been previous observed 
experimentally, endogenously, and clinically (Betts et al., 2017; Bilezikian et al., 2019; 
Calvi et al., 2001; Conigrave, 2016b; Costanzo, 2010; Crowell et al., 1984; Dobnig & 
Turner, 1995; Ishizuya et al., 1997; Keller & Kneissel, 2005; Lau et al., 2012; Locklin et 
al., 2003a; Lou et al., 2018; Manolagas, 2000; Ogita et al., 2008; Yukata et al., 2018).  
In most of this data, the 50nM-continuous treatment groups exhibited the highest 
response to PTH. This trend is clearly observed in qualitative staining outcomes. By 
100nM-continous treatment, staining was the same or a bit decreased, potentially 
showing a slight catabolic effect of continuous treatment. 100nM-intermittent treatment 
seemed to exhibit about the same level of staining as 50nM-continuous treatment. Data 
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from other experimental methods (i.e. qPCR, Metabolic Seahorse Assay, cAMP-ELISA 
1hr+ samples) showed little to no difference between the continuous and intermittent 
treatment regimens but continued to show a response to increasing PTH doses. Because 
little difference between regimens was observed, future experimentation may require 
only one treatment regimen (either continuous or intermittent), saving both time and 
resources. Several other researchers have conducted in-vivo and in-vitro experimentation 
with only one type of PTH-treatment, usually intermittent for several ug/kg/day (in-vivo) 
or several hours/day (in-vitro) and noticed anabolic effects on bone (Alves de Oliveira et 
al., 2010; Jiang et al., 2019).  
While we hypothesize that no difference was noted between regimens due to the 
difficulty of modeling PTH treatment in-vitro, it is possible that longer than 7-day 
continuous exposure to PTH could lead to increased catabolic gene expression outcome 
using qPCR analysis (i.e. more anti-osteogenic, pro-adipogenic related gene expression). 
4.2: Revisiting the Hypothesis  
While a complete five-part hypothesis was explained in the Introduction, below is 
a summary of the current conclusions to each corresponding hypothesis part:  
1. PTH treatment promotes greater osteoblast and less adipocyte differentiation. 
As predicted, PTH treatment showed greater osteoblastogenesis in osteogenic 
stains and qPCR measures of osteoblast related genes. PTH treatment also suppressed 
adipocyte differentiation in ORO stained cells (in both osteogenic and adipogenic 
differentiation media), yet increased adipogenesis related genes in qPCR outcomes. We 
are uncertain why adipocyte-related genes increased with 7-day PTH treatment, but one 
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hypothesis is that the cells were switching from an anabolic effect of PTH to a catabolic 
effect of PTH. To confirm this hypothesis, qPCR of adipocyte-related genes would need 
to be measured after only several hours of PTH treatment to see if adipocyte genes are 
suppressed before they are increased. This information could also further elucidate a 
better model for continuous vs. intermittent PTH treatment.  
2. Zfp467 KO cells will show greater osteoblast and less adipocyte differentiation. 
Nearly all trials of osteoblast and adipocyte staining and qPCR analysis confirmed 
that the KO genotype showed greater osteogenic and decreased adipogenic potential, as 
compared to the WT. This was confirmed both qualitatively and quantitatively. This data 
supports that Zfp467 is involved in the PTH signaling pathway and that suppressing 
Zfp467 can lead to increased osteogenesis and an increased response to PTH treatment.  
3. PTH treatment will decrease the expression of Zfp467 in cells.  
In Quach et al.’s research, 1 hour of PTH treatment was associated with a 
significant 50% decrease in Zfp467 in differentiating mouse stromal osteoblastic cell 
lines (Quach et al., 2011). However, we found that 7-days of PTH treatment did not 
decrease Zfp467 expression levels in COB samples. qPCR data show a slight decrease in 
Zfp467 with intermittent PTH treatment for the WT genotype. Although this data is 
puzzling considering our hypothesized pathway, more data need to be collected before 
further conclusions on the effect of PTH treatment on Zfp467 expression are made.  
4. Zfp467 KO cells will show a constitutive upregulation of Pth1r and PTH1r. 
Our western blot data shows that the KO genotype has a 1.5-fold greater 
expression of PTH1r, as compared to WT, in both COBs and BMSCs. Furthermore, PTH 
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treatment increased Pth1r gene expression in the KO genotype. We propose the 
mechanism of ZFP467 suppressing PTH1r expression and that subsequent suppression of 
Zfp467, as in the KO cells, constitutively upregulates Pth1r (Figure 7). This model 
explains the increased sensitivity to treatment of the KO genotype observed in our data. 
5. A positive feedback loop: Zfp467 KO will exhibit an enhanced response to PTH. 
Staining (i.e. ALP, VK, ARS, and ORO) showed that the KO genotype had a 
significantly increased response to PTH treatment as compared to WT. ALP 
quantification measures showed that while WT had a 1.5-fold increase in staining after 
PTH treatment, KO cells showed a 2 to 2.5-fold increase in staining after treatment. VK 
and ARS staining paralleled this finding qualitatively. ORO stain quantification showed a 
2 to 3-fold decrease in staining after treatment in the KO samples, as compared to no 
change in staining after treatment for the WT samples (continuous treatment). 
Corresponding intermittent treatment samples also showed less ORO in KO samples as 
compared to WT samples. 
In nearly all our qPCR osteoblast (i.e. Alp, Sp7, and Rankl) gene expression 
analyses, we observed a large increase in gene expression with increased PTH dosage in 
the KO genotype, while WT showed a smaller increase or often no change. The KO-
treated samples increased up to 4.5-fold in osteoblast gene expression as compared to 
KO-vehicle, while WT-treated samples only increased at most 1.5-fold compared to WT-
vehicle. Further still, most of the WT-treated samples were not significantly different 
from WT-vehicle.  
Both the staining and qPCR data support an increased sensitivity of the KO 
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genotype to PTH treatment, supporting a feedback loop between ZFP467 and PTH1r. 
4.3: Limitation of the Study 
There are a few limitations in our ALP and VK data. First, all ALP stains did not 
cover the entire well as seen in published literature (Ishizuya et al., 1997; Kawai et al., 
2011). However, we do not believe this affected our conclusions because the ALP trends 
match up to five sets of VK, ARS, and qPCR data. Furthermore, we planned to VK stain 
COBs at days 14-21 of osteoblastogenesis, like most literature (Alves de Oliveira et al., 
2010; Bilezikian et al., 2019; Ishizuya et al., 1997; Kawai et al., 2011). However, some 
COB cultures began to peel at day 7, possibly due to extended time out of the incubator 
during PTH treatment. Peeled cultures were stained at day 7 of osteogenic differentiation 
and results showed minimal mineralization present. We are unsure if these represent 
artifact or true mineralization. However, even with peeling of some VK cultures, ARS 
stains support the same trends as observed in VK. Further still, ARS staining showed 
even clearer trends between genotype and treatment dose, further supporting our 
conclusions of increased sensitivity to PTH in the KO genotype. Even with these 
limitations, we still conclude that the KO genotype shows an increased response to PTH 
treatment as compared to WT, possibly due to an upregulation of PTH1r.  
There are a few other limitations in our research. First, the scope of this study 
involved five sets of experimentations with calvarial osteoblast cells. Yet, it is possible 
that PTH affects Zfp467 differently in different cell types. Researchers Calvi et al. found 
that PTH has different effects on trabecular vs. cortical bone which could be extrapolated 
to different results in calvarial vs. bone marrow stromal cell types (Calvi et al., 2001). 
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While our data shows consistent results between COB and BMSCs, five sets of 
experimentation has only been performed on COBs. Secondly, the age of the mice used 
for calvarial isolation could have affected the results. We observed more adipose 
development in osteogenic cultures of mice that had been isolated at 5-7 days of age. 
Less adipose developed in cultures of 3-day old mice. However, we would like a purer 
osteogenic culture for more accurate results. In the future experimentation, we would like 
to isolate calvarial from 0 to 3-day old mice, instead of 3 to 7-day old mice. Lastly, in-
vitro modeling is very precise and involved, therefore, small calculation or pipetting 
errors could have occurred. However, because our results were consistent and replicable 
by various researchers in the lab, we don’t believe significant errors were made.  
4.4: Future Experimentation  
To further the osteogenic staining data, we would like to use a more precise ALP 
quantification method and conduct more ARS trials. We would like to use a calorimetric 
ALP-quantitative assay kit (Abcam, Burlingame, CA). We would also like to conduct at 
least three sets of ARS staining; only one set on COBs and BMSCs was reported in this 
data. Although we observed very consistent osteogenic stain results, these future 
experiments would further strengthen our data. 
Using qPCR analysis, we would like to further assess whether PTH 
downregulates Zfp467 expression and whether Zfp467’s role is generalizable across cell 
types. Although we did not observe PTH to downregulate Zfp467, we would like to 
analyze COBs and BMSCs exposed to different durations of treatment before drawing a 
conclusion. These durations would include 1h, 6h, 12h, and 24h of PTH exposure on five 
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sets of COBs and BMSCs. In our data, these four time-points were collected for cAMP-
ELISA and metabolic respiration (Seahorse 96XF) experiments only. However, qPCR 
analysis on these exposure durations could elucidate the early effects of PTH on gene 
expression and hopefully replicate Quach et al.’s data of 1h PTH treatment 
downregulating Zfp467. Furthermore, data on BMSCs could elucidate whether Zfp467’s 
pro-adipogenic and anti-osteogenic role holds across multiple cell types. While several 
trials of untreated BMSCs were stained and showed trends parallel to COBs (Figures 17-
20), trials of treated BMSCs were not conducted. Future experiments could include PTH 
treatment on BMSCs with both staining and qPCR outcome measures. These data could 
further confirm a generalizable role for Zfp467 across multiple cell types. Lastly, more 
qPCR genes could be analyzed. These genes could include the following: (1) More 
osteogenic or adipogenic related genes to further support current data; (2) Metabolically 
related genes to further elucidate mitochondrial activity suppression observed in the KO 
samples; (3) Systemic hormones like insulin like growth factor-1 to observe how 
systemic hormones are affected by PTH treatment and Zfp467. 
Lastly, from our cAMP-ELISA data, we questioned whether the KO genotype is 
switching to another signaling pathway after 10 minutes of PTH exposure. One 
hypothesis is that cells are switching to the PLC/PKC pathway, which is also known to be 
activated by PTH1r (Conigrave, 2016b). However, we believe this is unlikely because the 
literature shows that activation of the PLC/PKC pathway is usually seen within the first 
minute of PTH exposure (Treyball et al., 2020). By 10 minutes of PTH exposure, we 
predict that the PLC/PKC pathway has already been activated. Regardless, we would like 
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to measure intracellular calcium levels as a measure of PLC/PKC activation using a 
FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA). We 
would also like to use western blot to detect the expression level of phosphate-PKC or its 
downstream targets (i.e. phosphate-p38, phosphate-JNK, and phosphate-ERK) on 
samples exposed to PTH for 10+ minutes to further confirm if the cells are using the PKC 
pathway. This data could further explain the downstream targets of PTH1r and the 
sensitivity of the KO genotype. 
4.5: Conclusion 
Breaking ground in the intersection of Zinc Finger Protein 467 and PTH 
treatment, our data shows an enhanced osteogenic potential and increased sensitivity to 
PTH treatment in the Zfp467 KO genotype through in-vitro models and gene analysis 
trials. Our data support a definite, yet inverse involvement of Zfp467 in the PTH 
signaling pathway. We propose a positive feedback loop where the suppression of Zfp467 
leads to a continual increase of PTH1r, and therefore an enhanced response to treatment. 
Furthermore, our data supports the pro-adipogenic role of Zfp467 and our KO samples 
show decreased cellular respiration, although more data is needed to understand Zfp467’s 
role in cellular respiration. 
If a translational correlate could be found for this research, such as a 
pharmacological intervention targeting Zfp467 in humans, patients may better respond to 
PTH analogs. Osteoporosis treatment for millions of patients world-wide could be 
improved. Although decades more of research are needed before this point, we hope our 
investigations are groundwork for further research elucidating Zfp467’s role in enhancing 
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Table 1: A complete list of qPCR genes analyzed 
 Genes 
1 Adiponectin  AdipoQ 
2 Alkaline phosphatase Alp 
3 CCAAT/enhancer-binding protein alpha C/ebpa 
4 Collagen 1 Col-1 
5 Fatty acid-binding protein 4 Fapb4 
6 Lymphoid enhancer-binding factor 1 Lef-1 
7 Osterix Sp7 
8 Parathyroid hormone receptor 1 Pthr1 
9 Peroxisome proliferator activated receptor gamma Pparγ 
10 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Pgc1a 
11 Receptor activator of nuclear factor kappa-B ligand Rankl 
12 Runx family of transcription factor 2 Runx2 
13 Sclerostin Sost 
14 Zinc finger protein 423 Zfp467 
15 Zinc finger protein 467 Zfp423 
16 Zinc finger protein 521 Zfp521 
17 Beta-Actin β-actin 
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